Genmab locked in J&J royalty payments dispute
24-09-2020
Gilead to buy Immunomedics for $21bn
14-09-2020
Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal
03-08-2020
J&J wants $25m over ‘contaminated’ fake medical tools
29-06-2020
sundryphotography / Shutterstock.com
Johnson & Johnson (J&J) is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Johnson & Johnson, J&J, Momenta Pharmaceuticals, Sanofi, Principia Biopharma, M&A, mergers and acquisitions, autoimmune, biotech
